Virtual Challenging Case Clinic: Multiple Myeloma

  • Engage with leading experts to strategize on therapeutic options for your patients
  • Stay up to date on novel agents approved for the treatment of multiple myeloma, and assess recommended sequencing of therapy
VCC Main image 2
Lonial Sagar

Course Director

Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Agenda

  • Welcome, Introductions, and Pre-session Survey
  • General Disease State and Treatment Guidelines
  • Expert Insights: Faculty-submitted cases
  • Case Presentation, Polling Questions, and Discussion
  • Q&A
  • Conclusion and Post-session Survey

Upcoming Webinars

JULY 20, 2022

Updates from ASCO and EHA
Suzanne Lentzsch, MD
Columbia University l New York, New York

SEPTEMBER 21, 2022

New Approvals and Advanced Targets in MM
Joshua Richter, MD
Icahn School of Medicine at Mount Sinai l New York, New York

NOVEMBER 16, 2022

Optimal Induction and Maintenance Therapies
Amrita Krishnan, MD
City of Hope l Duarte, California

JANUARY 18, 2023

Updates from ASH
Peter Voorhees, MD
Atrium Health l Charlotte, North Carolina

MARCH 15, 2023

Management of Early Relapse in the Evolving Treatment World
Krina Patel, MD, MSc
UT MD Anderson l Houston, Texas

This activity is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Recordings From Previous Webinars: 2022 Series

CAR T-cell Therapy: For Whom and When?

Nina Shah, MD

University of California San Francisco l San Francisco, California
Broadcast May 25, 2022
Recordings From Previous Webinars: 2021 Series

MM-associated AL Amyloidosis

Shaji Kumar, MD

Mayo Clinic | Rochester, Minnesota

Broadcast: March 2, 2022

Updates from ASH

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center | Houston, Texas

Broadcast: January 19, 2022

Aligning Induction Therapy for Each Patient

Saad Usmani, MD, MBA, FACP
Memorial Sloan Kettering Cancer Center | New York, New York
(as of 11/1/2021 onwards)

Broadcast: October 20, 2021

Agents Targeting BCMA

Noopur Raje, MD
Massachusetts General Hospital | Boston, Massachusetts

Broadcast: August 18, 2021

Updates from ASCO and EHA

Jonathan Kaufman, MD
Winship Cancer Institute of Emory University | Atlanta, Georgia

Broadcast: June 16, 2021

CAR T Cells for MM

Nina Shah, MD
UCSF | San Francisco, California

Broadcast on April 21, 2021

This activity is supported by independent educational grants from Bristol-Myers Squibb and Oncopeptides

Recordings From Previous Webinars: 2020 Series

Updates from ASH and Year in Review

Sagar Lonial, MD, FACP
Winship Cancer Institute of Emory University | Atlanta, Georgia

Broadcast on January 20, 2021

Emerging Therapeutic Options: What’s On the Horizon?

Adam Cohen, MD
University of Pennsylvania | Philadelphia, Pennsylvania

Broadcast on November 18, 2020

Treating Relapsed/Refractory MM: Sequencing of Therapies

Paul G. Richardson, MD
Dana-Farber Cancer Institute | Boston, Massachusetts

Broadcast on September 16, 2020

Updates from ASCO and EHA

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center | Houston, Texas

Broadcast on July 15, 2020

Maintenance Therapy Approaches

Nina Shah, MD
University of California, San Francisco | San Francisco, California

Broadcast on May 20, 2020

This activity is supported by independent educational grants from Bristol-Myers Squibb, GlaxoSmithKline LLC, and Oncopeptides

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other healthcare providers who treat patients with MM.

Learning Objectives
  • Evaluate best available evidence regarding the treatment of newly diagnosed and relapsed/refractory MM
  • Assess the implications of emerging clinical trial data regarding therapeutic approaches for patients with MM
  • Develop strategies to optimize the outcomes of complicated MM cases
Continuing Education

UNMC Joint Accreditation Logo December2020 1

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  
Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.